Related Experiment Video
Updated: Jun 6, 2026
14:34
A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
Published on: April 3, 2026
Identification of novel ASK1 inhibitors using virtual screening
Masako Okamoto1, Nae Saito, Hirotatsu Kojima
1Drug Discovery Department, Research & Development Division, PharmaDesign, Inc., 2-19-8 Hatchobori, Chuo-ku, Tokyo 104-0032, Japan. okamoto@pharmadesign.co.jp
Bioorganic & Medicinal Chemistry
|December 8, 2010
Summary
Researchers identified novel inhibitors for Apoptosis signal-regulating kinase 1 (ASK1), a key target for diseases like cancer and neurodegeneration. This discovery advances potential new treatments for these conditions.
Area of Science:
- Biochemistry and Molecular Biology
- Pharmacology
- Drug Discovery
Background:
- Apoptosis signal-regulating kinase 1 (ASK1/MAP3K5) is a critical mediator of stress-induced cell death and inflammation.
- ASK1 is recognized as a promising therapeutic target for various diseases, including cancer, cardiovascular disorders, and neurodegenerative conditions.
Purpose of the Study:
- To identify novel inhibitors of ASK1 through virtual screening.
- To explore potential therapeutic agents targeting ASK1-related pathologies.
Main Methods:
- Utilized virtual screening techniques.
- Screened a public chemical library from the Chemical Biology Research Initiative (CBRI) at the University of Tokyo.
Main Results:
- Successfully identified novel inhibitors of ASK1.
- The identified compounds represent potential leads for drug development.
Conclusions:
- The discovery of novel ASK1 inhibitors provides a foundation for developing new therapeutic strategies.
- These findings support ASK1 as a viable drug target for treating significant human diseases.
